In light of our findings, we propose that inhibition of PYK2, a common downstream effector of both IL8 and ErbB receptors, could potentiate the impact of ErbB and/or IL8 receptor inhibitors and attenuate breast cancer invasion and metastasis. This evidence concerns the gene CXCL8 and breast cancer.